The Institute for Molecular Cardiovascular Research, Uni ver sitäts klinikum Aachen, Medical Faculty, Rheinisch-Westfälische Technische Hochschule Pauwelsstrasse 30, 52074 Aachen, Germany.
Nat Rev Drug Discov. 2010 Feb;9(2):141-53. doi: 10.1038/nrd3048.
Atherosclerosis is a chronic inflammatory disease of the arterial wall that is characterized by a disturbed equilibrium of immune responses and lipid accumulation, leading to the development of plaques. The atherogenic influx of mononuclear cells is orchestrated by chemokines and their receptors. Studies using gene-deficient mice and antagonists based on peptides and small molecules have generated insight into targeting chemokine-receptor axes for treating atherosclerosis, which might complement lipid-lowering strategies and risk factor modulation. Combined inhibition of multiple chemokine axes could interfere with the contributions of chemokines to disease progression at specific cells, stages or sites. In addition, the recently characterized heterophilic interactions of chemokines might present a novel target for the treatment and prevention of inflammatory diseases such as atherosclerosis.
动脉粥样硬化是一种动脉壁的慢性炎症性疾病，其特征是免疫反应和脂质积累的平衡失调，导致斑块的形成。单核细胞的动脉粥样硬化流入是由趋化因子及其受体协调的。使用基因缺陷小鼠和基于肽和小分子的拮抗剂进行的研究为针对趋化因子-受体轴治疗动脉粥样硬化提供了深入了解，这可能补充降脂策略和危险因素调节。联合抑制多个趋化因子轴可能会干扰趋化因子在特定细胞、阶段或部位对疾病进展的贡献。此外，最近描述的趋化因子的异源相互作用可能为治疗和预防动脉粥样硬化等炎症性疾病提供一个新的靶点。
